Diet Polyphenol Curcumin Stimulates Hepatic Fgf21 Production and Restores Its Sensitivity in High-Fat-Diet–Fed Male Mice

We found previously that short-term curcumin gavage stimulated mouse hepatic fibroblast growth factor 21 (Fgf21) expression. Here we conducted mechanistic exploration and investigated the potential pathophysiological relevance on this regulation. Fgf21 stimulation was observed at messenger RNA and protein levels in mice with daily curcumin gavage for 4 or 8 days and in primary hepatocytes with curcumin treatment. Using peroxisome proliferator-activated receptor α (PPARα) agonist and antagonist, along with luciferase reporter and chromatin immune-precipitation approaches, we determined that curcumin stimulates Fgf21 transcription in a mechanism involving PPARα activation. High-fat diet (HFD) feeding also increased mouse hepatic and serum Fgf21 levels, whereas dietary curcumin intervention attenuated these increases. We found that HFD feeding reduced hepatic expression levels of genes that encode FGFR1 and βKlotho, PGC1α, and the targets of the PPARα-PGC1α axis, whereas concomitant curcumin intervention restored or partially restored their expression levels. Importantly, hepatocytes from HFD-fed mice showed a loss of response to FGF21 treatment on Erk phosphorylation and the expression of Egr1 and cFos; this response was restored in hepatocytes from HFD-fed mice with curcumin intervention. This investigation expanded our mechanistic understanding of the metabolic beneficial effects of dietary curcumin intervention involving the regulation of Fgf21 production and the attenuation of HFD-induced Fgf21 resistance.

[1]  M. Beekman,et al.  Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice , 2016, Scientific Reports.

[2]  C. Musante,et al.  PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  P. Leung,et al.  Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus , 2016, Medicinal research reviews.

[4]  Jeffrey R. Chabot,et al.  A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. , 2016, Cell metabolism.

[5]  F. Villarroya,et al.  Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice , 2016, Diabetes.

[6]  R. DiMarchi,et al.  FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties , 2015, Trends in Endocrinology & Metabolism.

[7]  I. G. Fantus,et al.  Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice. , 2015, The Journal of nutrition.

[8]  Xiaokun Li,et al.  Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model. , 2015, American journal of physiology. Endocrinology and metabolism.

[9]  Yuan Zhang,et al.  Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. , 2015, Biochimica et biophysica acta.

[10]  N. Stefan,et al.  Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes , 2015, Molecular metabolism.

[11]  C. Morrison,et al.  Protein-dependent regulation of feeding and metabolism , 2015, Trends in Endocrinology & Metabolism.

[12]  Yuan Zhang,et al.  Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. , 2015, Molecular endocrinology.

[13]  A. Xu,et al.  Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  T. Jin,et al.  Liver-Specific Expression of Dominant-Negative Transcription Factor 7-Like 2 Causes Progressive Impairment in Glucose Homeostasis , 2015, Diabetes.

[15]  S. Kliewer,et al.  Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding , 2014, Diabetes.

[16]  D. Schuppan,et al.  Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. , 2014, Gastroenterology.

[17]  Xiaokun Li,et al.  Inhibition of JNK Phosphorylation by a Novel Curcumin Analog Prevents High Glucose–Induced Inflammation and Apoptosis in Cardiomyocytes and the Development of Diabetic Cardiomyopathy , 2014, Diabetes.

[18]  G. Bray,et al.  FGF21 is an endocrine signal of protein restriction. , 2014, The Journal of clinical investigation.

[19]  H. Shulha,et al.  The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. , 2014, Cell metabolism.

[20]  T. Jin,et al.  p21-Activated protein kinases and their emerging roles in glucose homeostasis. , 2014, American journal of physiology. Endocrinology and metabolism.

[21]  A. Adams,et al.  Inventing new medicines: The FGF21 story☆ , 2013, Molecular metabolism.

[22]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[23]  Lingyun Zhu,et al.  The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis , 2013, Diabetes.

[24]  T. Jin,et al.  The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. , 2012, American journal of physiology. Endocrinology and metabolism.

[25]  S. Jirawatnotai,et al.  Curcumin Extract for Prevention of Type 2 Diabetes , 2012, Diabetes Care.

[26]  W. Ling,et al.  Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. , 2012, World journal of diabetes.

[27]  I. G. Fantus,et al.  Curcumin Prevents High Fat Diet Induced Insulin Resistance and Obesity via Attenuating Lipogenesis in Liver and Inflammatory Pathway in Adipocytes , 2012, PloS one.

[28]  Ranjeny Thomas,et al.  Targeting Curcusomes to Inflammatory Dendritic Cells Inhibits NF-κB and Improves Insulin Resistance in Obese Mice , 2011, Diabetes.

[29]  A. Xu,et al.  Research Design and Methods , 2005, Hormone Research in Paediatrics.

[30]  I. G. Fantus,et al.  Oltipraz upregulates the nuclear respiratory factor 2 alpha subunit (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice , 2011, Diabetologia.

[31]  A. Bookout,et al.  LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. , 2011, The Journal of clinical investigation.

[32]  Jian Xiao,et al.  Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile , 2010, PloS one.

[33]  A. Awad,et al.  Curcumin and obesity: evidence and mechanisms. , 2010, Nutrition reviews.

[34]  B. Aktas,et al.  Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease , 2010, European journal of clinical investigation.

[35]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[36]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[37]  A. Kharitonenkov FGFs and metabolism. , 2009, Current opinion in pharmacology.

[38]  T. Jin,et al.  The rho guanosine 5'-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell. , 2009, Endocrinology.

[39]  E. Maratos-Flier,et al.  A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. , 2009, American journal of physiology. Endocrinology and metabolism.

[40]  S. Kliewer,et al.  FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response , 2009, Proceedings of the National Academy of Sciences.

[41]  R. DeFronzo,et al.  Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.

[42]  A. Pfeiffer,et al.  Free Fatty Acids Link Metabolism and Regulation of the Insulin-Sensitizing Fibroblast Growth Factor-21 , 2009, Diabetes.

[43]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[44]  K. Oishi,et al.  Circadian expression of FGF21 is induced by PPARα activation in the mouse liver , 2008, FEBS letters.

[45]  M. Eriksson,et al.  The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. , 2008, Cell metabolism.

[46]  Kenny K. Wong,et al.  Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States , 2008, Molecular Pharmacology.

[47]  R. Leibel,et al.  Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. , 2008, Endocrinology.

[48]  S. Chung,et al.  Aldose Reductase Regulates Hepatic Peroxisome Proliferator-activated Receptor α Phosphorylation and Activity to Impact Lipid Homeostasis* , 2008, Journal of Biological Chemistry.

[49]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[50]  R. Prough,et al.  Modulation of Receptor Phosphorylation Contributes to Activation of Peroxisome Proliferator Activated Receptor α by Dehydroepiandrosterone and Other Peroxisome Proliferators , 2008, Molecular Pharmacology.

[51]  T. Lundåsen,et al.  PPARα is a key regulator of hepatic FGF21 , 2007 .

[52]  J. Flier,et al.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.

[53]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[54]  S. Kliewer,et al.  Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.

[55]  Yun-Fei Chen,et al.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.

[56]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[57]  A. Scalbert,et al.  Polyphenols and prevention of cardiovascular diseases , 2005, Current opinion in lipidology.

[58]  D. Kelly,et al.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.

[59]  B. Aggarwal,et al.  Curcumin, a component of turmeric: From farm to pharmacy , 2013, BioFactors.

[60]  A. Xu,et al.  Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[61]  T. Lundåsen,et al.  PPARalpha is a key regulator of hepatic FGF21. , 2007, Biochemical and biophysical research communications.

[62]  Gary Williamson,et al.  Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.